Related Experiment Videos
Anticoagulation in Congestive Cardiomyopathy: Steps Toward Defining the Great Unknown
1Cardiovascular Thrombosis Research Center, University of Massachusetts Medical School, Worcester, Massachusetts.
Insights
Congestive cardiomyopathy increases cardiac thrombus and thromboembolism risk. A proposed trial will compare aspirin, warfarin, and placebo to guide anticoagulation strategies for these high-risk patients.
Area of Science:
- Cardiology
- Thrombosis
- Pharmacology
Background:
- Congestive cardiomyopathy is linked to cardiac thrombus formation and systemic thromboembolism.
- Uncontrolled studies support anticoagulation, but definitive data is lacking.
- Risk factors for embolic events include thrombus presence, left ventricular dysfunction, and low apical flow.
Purpose of the Study:
- To address the need for a large, randomized controlled trial on anticoagulation in congestive cardiomyopathy.
- To compare the efficacy of aspirin, warfarin, and placebo in preventing thromboembolism.
- To provide evidence-based guidance for managing patients with congestive cardiomyopathy.
Main Methods:
- A multicenter trial is proposed.
- The trial will compare aspirin, warfarin, and placebo.
- Participants will be patients with congestive cardiomyopathy.
Main Results:
- No results are available as the trial is proposed, not yet conducted.
- The study aims to identify the optimal prophylactic strategy.
- Findings will inform clinical practice regarding anticoagulation.
Conclusions:
- Definitive data on anticoagulation in congestive cardiomyopathy is needed.
- A randomized trial is essential for evidence-based management.
- The proposed trial will clarify the role of aspirin and warfarin versus placebo.
Abstract:
It is generally agreed that congestive cardiomyopathy predisposes to the formation of cardiac thrombus and in turn systemic thromboembolism. Several uncontrolled studies have confirmed this association and have prompted wide-scale recommendations for long-term anticoagulation in these patients. Clinical studies have also attempted to identify patients at high risk for embolic events. The presence of cardiac thrombus, its topographic characteristics, the severity of left ventricular dysfunction, and decreased apical flow velocities may each represent markers of increased risk.Driven by the lack of definitive data addressing this issue, several pleas from the medical community have come forth for a large, randomized controlled trial of anticoagulation in congestive cardiomyopathy. Accordingly, a multicenter trial comparing aspirin, warfarin, or placebo as prophylaxis against thromboembolism has been proposed and if conducted will provide valuable information regarding the management of patients with congestive cardiomyopathy.